261 related articles for article (PubMed ID: 33249475)
1. Population Impact of Girls-Only Human Papillomavirus 16/18 Vaccination in The Netherlands: Cross-Protective and Second-Order Herd Effects.
Hoes J; Woestenberg PJ; Bogaards JA; King AJ; de Melker HE; Berkhof J; Hoebe CJPA; van der Sande MAB; van Benthem BHB;
Clin Infect Dis; 2021 Mar; 72(5):e103-e111. PubMed ID: 33249475
[TBL] [Abstract][Full Text] [Related]
2. Assessment of herd effects among women and heterosexual men after girls-only HPV16/18 vaccination in the Netherlands: A repeated cross-sectional study.
Woestenberg PJ; Bogaards JA; King AJ; Leussink S; van der Sande MA; Hoebe CJ; van Benthem BH;
Int J Cancer; 2019 Jun; 144(11):2718-2727. PubMed ID: 30426502
[TBL] [Abstract][Full Text] [Related]
3. HPV infections among young MSM visiting sexual health centers in the Netherlands: Opportunities for targeted HPV vaccination.
Woestenberg PJ; van Benthem BHB; Bogaards JA; King AJ; van der Klis FRM; Pasmans H; Leussink S; van der Sande MAB; Hoebe CJPA;
Vaccine; 2020 Apr; 38(17):3321-3329. PubMed ID: 32201140
[TBL] [Abstract][Full Text] [Related]
4. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
Woestenberg PJ; King AJ; van der Sande MA; Donken R; Leussink S; van der Klis FR; Hoebe CJ; Bogaards JA; van Benthem BH; ;
J Infect; 2017 Apr; 74(4):393-400. PubMed ID: 28126492
[TBL] [Abstract][Full Text] [Related]
5. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study.
Chow EPF; Machalek DA; Tabrizi SN; Danielewski JA; Fehler G; Bradshaw CS; Garland SM; Chen MY; Fairley CK
Lancet Infect Dis; 2017 Jan; 17(1):68-77. PubMed ID: 27282422
[TBL] [Abstract][Full Text] [Related]
6. Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors.
Woestenberg PJ; King AJ; van Benthem BHB; Donken R; Leussink S; van der Klis FRM; de Melker HE; van der Sande MAB; Hoebe CJPA; Bogaards JA;
J Infect Dis; 2018 Jan; 217(2):213-222. PubMed ID: 29140439
[TBL] [Abstract][Full Text] [Related]
7. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study.
Tabrizi SN; Brotherton JM; Kaldor JM; Skinner SR; Liu B; Bateson D; McNamee K; Garefalakis M; Phillips S; Cummins E; Malloy M; Garland SM
Lancet Infect Dis; 2014 Oct; 14(10):958-66. PubMed ID: 25107680
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study.
Chow EP; Danielewski JA; Fehler G; Tabrizi SN; Law MG; Bradshaw CS; Garland SM; Chen MY; Fairley CK
Lancet Infect Dis; 2015 Nov; 15(11):1314-23. PubMed ID: 26201300
[TBL] [Abstract][Full Text] [Related]
9. High Effectiveness of the Bivalent Human Papillomavirus (HPV) Vaccine Against Incident and Persistent HPV Infections up to 6 Years After Vaccination in Young Dutch Women.
Donken R; King AJ; Bogaards JA; Woestenberg PJ; Meijer CJLM; de Melker HE
J Infect Dis; 2018 Apr; 217(10):1579-1589. PubMed ID: 29409034
[TBL] [Abstract][Full Text] [Related]
10. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study.
Kavanagh K; Pollock KG; Cuschieri K; Palmer T; Cameron RL; Watt C; Bhatia R; Moore C; Cubie H; Cruickshank M; Robertson C
Lancet Infect Dis; 2017 Dec; 17(12):1293-1302. PubMed ID: 28965955
[TBL] [Abstract][Full Text] [Related]
11. Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study.
Mesher D; Panwar K; Thomas SL; Beddows S; Soldan K
BMJ Open; 2016 Feb; 6(2):e009915. PubMed ID: 26868944
[TBL] [Abstract][Full Text] [Related]
12. Vaccine Effectiveness Following Routine Immunization With Bivalent Human Papillomavirus (HPV) Vaccine: Protection Against Incident Genital HPV Infections From a Reduced-Dosing Schedule.
Hoes J; King AJ; Klooster TMSV; Berkhof J; Bogaards JA; de Melker HE
J Infect Dis; 2022 Sep; 226(4):634-643. PubMed ID: 33964158
[TBL] [Abstract][Full Text] [Related]
13. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence.
Bogaards JA; Coupé VM; Xiridou M; Meijer CJ; Wallinga J; Berkhof J
Epidemiology; 2011 Jul; 22(4):505-15. PubMed ID: 21540743
[TBL] [Abstract][Full Text] [Related]
14. Non-Vaccine-Type Human Papillomavirus Prevalence After Vaccine Introduction: No Evidence for Type Replacement but Evidence for Cross-Protection.
Saccucci M; Franco EL; Ding L; Bernstein DI; Brown D; Kahn JA
Sex Transm Dis; 2018 Apr; 45(4):260-265. PubMed ID: 29465705
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial.
Gray P; Kann H; Pimenoff VN; Eriksson T; Luostarinen T; Vänskä S; Surcel HM; Faust H; Dillner J; Lehtinen M
PLoS Med; 2021 Jun; 18(6):e1003588. PubMed ID: 34097688
[TBL] [Abstract][Full Text] [Related]
16. Substantial Decline in Vaccine-Type Human Papillomavirus (HPV) Among Vaccinated Young Women During the First 8 Years After HPV Vaccine Introduction in a Community.
Kahn JA; Widdice LE; Ding L; Huang B; Brown DR; Franco EL; Bernstein DI
Clin Infect Dis; 2016 Nov; 63(10):1281-1287. PubMed ID: 27655996
[TBL] [Abstract][Full Text] [Related]
17. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia.
Regan DG; Philp DJ; Hocking JS; Law MG
Sex Health; 2007 Sep; 4(3):147-63. PubMed ID: 17931528
[TBL] [Abstract][Full Text] [Related]
18. The impact of over ten years of HPV vaccination in England: Surveillance of type-specific HPV in young sexually active females.
Checchi M; Mesher D; Panwar K; Anderson A; Beddows S; Soldan K
Vaccine; 2023 Oct; 41(45):6734-6744. PubMed ID: 37821315
[TBL] [Abstract][Full Text] [Related]
19. Effects of 2 and 3 Vaccinations With the Bivalent Human Papillomavirus (HPV) Vaccine on the Prevalence and Load of HPV in Clearing and Persistent Infections in Young Women.
van Eer K; Middeldorp M; Dzebisasjvili T; Lamkaraf N; de Melker HE; Steenbergen RDM; King AJ
J Infect Dis; 2023 Oct; 228(8):1012-1022. PubMed ID: 36988110
[TBL] [Abstract][Full Text] [Related]
20. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G
BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]